Targeting cancer using KAT inhibitors to mimic lethal knockouts
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Two opposing enzyme classes regulate fundamental elements of genome maintenance, gene regulation and metabolism, either through addition of an acetyl moiety by histone acetyltransferases (HATs) or its removal by histone de-acetyltransferases (HDAC), and are exciting targets for drug development. Importantly, dysfunctional acetylation has been implicated in numerous diseases, including cancer. Within the HAT superfamily the MYST family holds particular interest, as its members are directly involved in the DNA damage response and repair pathways and crucially, several members have been shown to be down-regulated in common cancers (such as breast and prostate). In the present study we focus on the development of lysine (K) acetyltransferase inhibitors (KATi) targeting the MYST family member Tip60 (Kat5), an essential protein, designed or discovered through screening libraries. Importantly, Tip60 has been demonstrated to be significantly down-regulated in many cancers which urgently require new treatment options. We highlight current and future efforts employing these KATi as cancer treatments and their ability to synergize and enhance current cancer treatments. We investigate the different methods of KATi production or discovery, their mechanisms and their validation models. Importantly, the utility of KATi is based on a key concept: using KATi to abrogate the activity of an already down-regulated essential protein (effectively creating a lethal knockout) provides another innovative mechanism for targeting cancer cells, while significantly minimizing any off-target effects to normal cells. This approach, combined with the rapidly developing interest in KATi, suggests that KATi have a bright future for providing truly personalized therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
KAT5 tyrosine phosphorylation couples chromatin sensing to ATM signalling
Kaidi, A., & Jackson, S. P. (2013) · Nature · doi:10.1038/nature12201 · Cited by 167
RetractedHistone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515
A role for the Tip60 histone acetyltransferase in the acetylation and activation of ATM
Sun, Y., Jiang, X., Chen, S., Fernandes, N., & Price, B. D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504211102 · Cited by 738
Murr, R., Loizou, J. I., Yang, Y.-G., Cuenin, C., Li, H., Wang, Z.-Q., & Herceg, Z. (2006) · Nature Cell Biology · doi:10.1038/ncb1343 · Cited by 613
Histone H3 methylation links DNA damage detection to activation of the tumour suppressor Tip60
Sun, Y., Jiang, X., Xu, Y., Ayrapetov, M. K., Moreau, L. A., Whetstine, J. R., & Price, B. D. (2009) · Nature Cell Biology · doi:10.1038/ncb1982 · Cited by 454
DNA Damage-Induced Acetylation of Lysine 3016 of ATM Activates ATM Kinase Activity
Sun, Y., Xu, Y., Roy, K., & Price, B. D. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01382-07 · Cited by 319
Tip60: Connecting chromatin to DNA damage signaling
Sun, Y., Jiang, X., & Price, B. D. (2010) · Cell Cycle · doi:10.4161/cc.9.5.10931 · Cited by 230
Cited by
Lifespan-increasing drug nordihydroguaiaretic acid inhibits p300 and activates autophagy
Tezil, T., Chamoli, M., Ng, C.-P., Simon, R. P., Butler, V. J., Jung, M., Andersen, J., Kao, A. W., & Verdin, E. (2019) · npj Aging and Mechanisms of Disease · doi:10.1038/s41514-019-0037-7 · Cited by 40
Chen, L., Qing, W., Yi, Z., Lin, G., Peng, Q., & Zhou, F. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.701760 · Cited by 31
“NU9056 is a specific inhibitor of KAT5 (16) related to the inhibition of NLRP3 inflammasome (15).”
BackgroundInfluentialMinisini, M., Di Giorgio, E., Kerschbamer, E., Dalla, E., Faggiani, M., Franforte, E., Meyer-Almes, F.-J., Ragno, R., Antonini, L., Mai, A., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac081 · Cited by 28
Metadata
- Authors
- Brown, J. A. L., Bourke, E., Eriksson, L. A., & Kerin, M. J.
- Venue
- Biochemical Society Transactions
- Publisher
- Portland Press Ltd.
- Published
- 2016-08-15
- Volume
- 44
- Issue
- 4
- Pages
- 979-986
- ISSN
- 0300-5127 (ISSN-L)
- 1470-8752
- OpenAlex
- W2518453524
- Cited by
- 64
- References
- 7
- FWCI
- 2.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.